

- 10.8.2026
- News
- Stanford Research
Veterans Experience Major PTSD and Depression Relief From Psychedelic Drug Ibogaine
This news report examines Stanford Medicine’s one-year follow-up study of Special Operations veterans who received ibogaine treatment, supported in part by VETS, and how the findings add to the growing body of research and federal attention on psychedelic-assisted therapy for veterans.

- 10.6.2026
- Stanford Research
- News
One year after taking ibogaine, veterans find continued relief from PTSD
A new Stanford Medicine study published in Translational Psychiatry follows Special Operations veterans for one year after ibogaine treatment, funded by VETS at a vetted, third-party facility, offering the most extensive look to date at the long-term potential of this therapy for PTSD, depression, and anxiety.
- 1.30.2026
- Stanford Research
Men’s Journal: Study — New Psychedelic Drug Combo Improves PTSD
Reports on the mystical-experience paper, noting PTSD symptom reductions in 30 male veterans after magnesium–ibogaine treatment. It presents the findings as preliminary support for larger PTSD trials.
- 8.1.2025
- Stanford Research
Neurology Advisor: Magnesium–Ibogaine May Be Beneficial for Combat Veterans With TBI
Reports that magnesium–ibogaine may benefit combat veterans with TBI based on observed resting-state brain-wave changes. The piece focuses on altered cortical oscillations and links those signals to psychiatric and cognitive outcomes.
